ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2414

A Retrospective Comparative Analysis of Cardiovascular Risk Factors, Atherosclerotic Cardiovascular Disease and Statin Use as Secondary Prevention in a Cohort of Patients with Systemic Lupus Erythematosus versus Without Rheumatological Disease from a Single-Center Patient Registry
Abstract Number: 1484

A Retrospective Evaluation of Glucagon-like Peptide-1 Receptor Agonists in SLE Patients
Abstract Number: 1871

A Seropositive RA Polygenic Risk Score Does Not Predict Progression to RA in an ACPA Positive Population
Abstract Number: 2217

A Significant Alteration in Circulating Endocannabinoid Levels in Rheumatoid Arthritis and Fibromyalgia Syndrome Patients and Its Correlation with Diseases Severity
Abstract Number: 2302

A Specific Molecular Profiling of Secreted Rheumatoid Factors in Sjögren’ S Disease Patients with Lymphoma
Abstract Number: 1358

A Step Towards Personalised Medicine – Development and Efficacy of Machine Learning Based Smart-Web Application for Prediction of Steroid Induced Hyperglycemia in Patients with Rheumatoid Arthritis and Other Autoimmune Rheumatic Diseases
Abstract Number: 2032

A Systematic Review of Treatment Strategies in VEXAS Syndrome
Abstract Number: 1041

A Theory of Change for Patient-Initiated Follow-Up Care in Rheumatoid Arthritis
Abstract Number: 1791

A Transcriptomic Lupus Activity Signature Associates with Cardiovascular Function
Abstract Number: 0544

A Two-year Comparison of Spinal and Hip Mobility Between Axial Spondyloarthritis and Chronic Back Pain Patients in the SPondyloArthritis Caught Early (SPACE) Cohort
Abstract Number: 0694

A Unified Vascular Phenotype Score Identifies Systemic Sclerosis Endotypes and Predicts Prognostic Outcomes: Results from the EUSTAR Database
Abstract Number: 1642

A Urinary Biomarker Panel to Predict the Probability of Histologically Active Lupus Nephritis
Abstract Number: L14

A Withdrawal Study of Colchicine in Behçet Syndrome
Abstract Number: L12

A-319, a CD3 X CD19 T Cell Engager (TCE), for the Treatment of Severe/Refractory SLE: Early Evidence of Rapid Reset of Disease-Specific Autoimmunity
Abstract Number: 1851

Aberrant Tfh Cells Generated by Th17 Cell Plasticity in the Gut Promote Autoimmune Arthritis

« Previous Page
1
…
5
6
7
8
9
…
182
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].